Century Therapeutics (IPSC)
(Delayed Data from NSDQ)
$1.54 USD
+0.08 (5.48%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $1.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Century Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 5 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 2 | 5 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 149 | 139 | 95 | 54 | 0 |
Income After Depreciation & Amortization | -147 | -134 | -95 | -54 | 0 |
Non-Operating Income | 12 | 4 | 0 | 1 | NA |
Interest Expense | 1 | 1 | 1 | 0 | NA |
Pretax Income | -135 | -131 | -96 | -54 | NA |
Income Taxes | 2 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -137 | -131 | -96 | -54 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -137 | -131 | -96 | -54 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -137 | -125 | -91 | -52 | 0 |
Depreciation & Amortization (Cash Flow) | 9 | 9 | 4 | 1 | NA |
Income After Depreciation & Amortization | -147 | -134 | -95 | -54 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 59.31 | 57.76 | 32.39 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.08 | -2.27 | -2.96 | NA | NA |
Diluted Net EPS (GAAP) | -2.30 | -2.27 | -2.96 | NA | NA |
Fiscal Year end for Century Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.77 | 0.86 | 0.27 | 0.15 | 0.10 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.77 | 0.86 | 0.27 | 0.15 | 0.10 |
SG&A, R&D, and Dept/Amort Expenses | 35.53 | 32.16 | 27.67 | 35.78 | 35.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | -34.76 | -31.30 | -27.40 | -35.63 | -35.08 |
Non-Operating Income | 3.57 | 3.25 | 3.50 | 3.50 | 2.87 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 |
Pretax Income | -31.19 | -28.06 | -40.27 | -32.13 | -32.34 |
Income Taxes | 0.02 | 0.00 | -0.87 | 0.59 | 0.95 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -31.21 | -28.06 | -39.40 | -32.72 | -33.29 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -31.21 | -28.06 | -39.40 | -32.72 | -33.29 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 82.09 | 62.30 | 60.61 | 59.45 | 59.25 |
Diluted EPS Before Non-Recurring Items | -0.38 | -0.45 | -0.49 | -0.55 | -0.56 |
Diluted Net EPS (GAAP) | -0.38 | -0.45 | -0.66 | -0.55 | -0.56 |